{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"PACTO","nct_id":"NCT02767557","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pacto-nct02767557. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PACTO","arms":[{"description":"Tocilizumab:\n\n8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.\n\nGemcitabine:\n\n1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.\n\nNab-Paclitaxel:\n\n125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.","label":"Tocilizumab & Gemcitabine and nab-Paclitaxel","type":"EXPERIMENTAL"},{"description":"Gemcitabine:\n\n1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.\n\nNab-Paclitaxel:\n\n125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.","label":"Gemcitabine and nab-Paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["Celgene"],"completion_date":{"date":"2023-01-01","type":"ACTUAL"},"conditions":["Unresectable Pancreatic Carcinoma"],"enrollment":{"count":147,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tocilizumab","otherNames":["(ACTEMRA®)"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"nab-Paclitaxel","otherNames":["ABRAXANE®"],"type":"DRUG"}],"last_update":"2023-09-22","lead_sponsor":"Herlev Hospital","official_title":"A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-08-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival at 6 months","timeFrame":"Approximately up to 6 months."}],"references":[{"citation":"Kjaer LK, Theile S, Madsen K, Johansen JS, Holmstrom MO, Andersen MH, Chen IM. Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer. Immun Inflamm Dis. 2026 Oct;14(10):e70545. doi: 10.1002/iid3.70545.","pmid":"42836590","type":"DERIVED"},{"citation":"Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, Dajani O, Lim KZM, Lorentzen T, Gaafer O, Koniaris LG, Ferreira AC, Neelon B, Guttridge DC, Ostrowski MC, Zimmers TA, Nielsen D. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. J Clin Oncol. 2025 Jun 20;43(18):2107-2118. doi: 10.1200/JCO.23.01965. Epub 2025 May 12.","pmid":"40354592","type":"DERIVED"}],"start_date":{"date":"2017-01-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients","url":"https://clinicaltrials.gov/study/NCT02767557"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pacto-nct02767557"}